Glaxosmithkline plc, of London, won FDA approval for Incruse Ellipta (umeclidinium), its anticholinergic for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.